Ptc Therapeutics (PTCT) Non-Current Debt (2012 - 2026)

Ptc Therapeutics' Non-Current Debt history runs 13 years deep, the most recent figure standing at $535.5 million for Q2 2026.

• In Q2 2026, Non-Current Debt rose 87.24% year-over-year to $535.5 million; the TTM figure through Jun 2026 stood at $535.5 million (up 87.24% YoY), while the FY2025 annual figure was $286.6 million, changed 0.43% from the prior year.
• Non-Current Debt for Q2 2026 stood at $535.5 million, up from $286.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $573.2 million in Q3 2023, with the low at $282.2 million in Q1 2022.
• The 5-year median for Non-Current Debt is $285.6 million (2024), against an average of $372.2 million.
• The sharpest annual moves came in 2022 and 2023: Non-Current Debt surged 102.81% in 2022, then tumbled 50.29% in 2023.
• Ptc Therapeutics' Non-Current Debt stood at $571.7 million in 2022, then sank by 50.29% to $284.2 million in 2023, then rose by 0.42% to $285.4 million in 2024, then climbed by 0.43% to $286.6 million in 2025, then soared by 86.83% to $535.5 million in 2026.
• Business Quant data shows PTCT's Non-Current Debt at $535.5 million in Q2 2026, $286.6 million in Q4 2025, and $286.0 million in Q2 2025.